This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n13https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Medicaid_Drug_Rebate_Program
rdf:type
dbo:Work
rdfs:label
Medicaid Drug Rebate Program
rdfs:comment
The Medicaid Drug Rebate Program is a program in the United States that was created by the Omnibus Budget Reconciliation Act of 1990 (OBRA'90). The program establishes mandatory rebates that drug manufacturers must pay state Medicaid agencies related to the dispensing of outpatient prescription drugs covered by Medicaid. To participate in the program, drug manufacturers must have a National Drug Rebate Agreement with the Secretary of the Department of Health and Human Services (HHS). As of 2020, approximately 600 pharmaceutics companies participated in the Medicaid Drug Rebate Program. Rebate amounts are confidential under section 1927(b)(3)(D) of the Social Security Act.
dcterms:subject
dbc:Medicare_and_Medicaid_(United_States)
dbo:wikiPageID
14536890
dbo:wikiPageRevisionID
1119930018
dbo:wikiPageWikiLink
dbr:United_States_Secretary_of_Health_and_Human_Services dbr:Health_care_reform dbr:Medicaid dbr:Medicaid_managed_care dbr:United_States_Consumer_Price_Index dbr:Bart_Stupak dbr:Omnibus_Budget_Reconciliation_Act_of_1990 dbr:Food_and_Drug_Administration dbr:Manufacturers dbr:United_States dbr:Pharmaceutics dbr:Patient_Protection_and_Affordable_Care_Act dbr:2010_United_States_federal_budget dbr:Congressional_Budget_Office dbr:111th_United_States_Congress dbr:Barack_Obama dbr:Jeff_Bingaman dbr:Medicare,_Medicaid,_and_SCHIP_Balanced_Budget_Refinement_Act_of_1999 dbc:Medicare_and_Medicaid_(United_States) dbr:340B_Drug_Pricing_Program dbr:Social_Security_Act dbr:Drug
owl:sameAs
wikidata:Q6806243 freebase:m.03d6ylw n13:4s8sF
dbp:wikiPageUsesTemplate
dbt:Reflist
dbo:abstract
The Medicaid Drug Rebate Program is a program in the United States that was created by the Omnibus Budget Reconciliation Act of 1990 (OBRA'90). The program establishes mandatory rebates that drug manufacturers must pay state Medicaid agencies related to the dispensing of outpatient prescription drugs covered by Medicaid. To participate in the program, drug manufacturers must have a National Drug Rebate Agreement with the Secretary of the Department of Health and Human Services (HHS). As of 2020, approximately 600 pharmaceutics companies participated in the Medicaid Drug Rebate Program. Rebate amounts are confidential under section 1927(b)(3)(D) of the Social Security Act. The Medicaid Drug Rebate Program also provides for savings in other Federal health care programs. Signing the National Drug Rebate Agreement also requires drug manufacturers to enter into agreements for the 340B Drug Pricing Program as well as the Federal Supply Schedule.
gold:hypernym
dbr:Program
prov:wasDerivedFrom
wikipedia-en:Medicaid_Drug_Rebate_Program?oldid=1119930018&ns=0
dbo:wikiPageLength
5892
foaf:isPrimaryTopicOf
wikipedia-en:Medicaid_Drug_Rebate_Program